Statins may increase the risk of myasthenia gravis and ocular myastheniaA Health Canada safety review concludes that there is a possible link between statin (HMG-CoA reductase inhibitor) use and the risk of myasthenia gravis. Specialty pharmacy a rapidly emerging area of practice At Neighbourhood Pharmacies of Canada’s annual Specialty Pharmacy Summit, the message was clear. Community pharmacies should no longer feel excluded from the specialty pharmacy arena. 5 clinical pearls for optimizing levothyroxine therapy Pharmacists can play an important role in screening patients for hypothyroidism. Health Canada advisory: Olanzapine From our December drug news roundup, check out this key Health Canada advisory relating to risk of SIADH and hyponatremia. Six new drug indications pharmacists and physicians should know about As pat of our December drug news roundup, here are six new indications for existing drugs. New product: Uplizna Get the info you need on this new product, part of our drug news roundup for December. New product: Comirnaty Get the info you need on this new product, part of our drug news roundup for December. New product: Imdelltra Get the info you need on this new product, part of our drug news roundup for December. New product: Voydeya: an oral complement inhibitor Get the info you need on this new product, part of our drug news roundup for December. New product: Zilbrysq for myasthenia gravis Get the info you need on this new product, part of our drug news roundup for December. First Previous 24 25 26 27 28 Next Last
